Therapeutics News and Research

RSS

Mosquito protein study could lead to therapeutics against deadly viruses

The mosquito protein AEG12 strongly inhibits the family of viruses that cause yellow fever, dengue, West Nile, and Zika and weakly inhibits coronaviruses, according to scientists at the National Institutes of Health (NIH) and their collaborators.

10 Mar 2021

NTU scientists design new compound that could help reduce overactive immune response

When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.

10 Mar 2021

Tiny antibodies naturally generated by llamas can be effective against COVID-19

As the fight against COVID-19 continues, scientists have turned to an unlikely source for a potentially effective treatment: tiny antibodies naturally generated by llamas.

10 Mar 2021

New compound can reduce overactivation without impairing the body's immunity response

10 Mar 2021

Both ventral and dorsal surgeries improve outcomes in patients with cervical spondylotic myelopathy

Affecting the vast majority of people older than 65, cervical spondylotic myelopathy (CSM) is the leading cause of spinal cord dysfunction in the United States and across the world.

10 Mar 2021

New analysis shows SARS-CoV-2 mutations rarely persist in subsequent transmissions

An analysis of SARS-CoV-2 genome diversity in more than 1,000 people in the United Kingdom suggests that if viral mutations do arise, they can be transmitted in some cases but they rarely persist in subsequent transmissions.

9 Mar 2021

Project Helios launched to unlock new approaches in small molecule drug discovery

The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.

9 Mar 2021

Five herbal medicines show potent activity against Babesia duncani in the lab

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data finding that five herbal medicines had potent activity compared to commonly-used antibiotics in test tubes against Babesia duncani, a malaria-like parasite found on the West Coast of the U.S. that causes the disease babesiosis.

9 Mar 2021

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

A phase 2 clinical trial is underway at Columbia University and NewYork-Presbyterian to test an investigational gene therapy for dry age-related macular degeneration, a progressive, chronic eye disease with no cure and a leading cause of blindness in the United States.

9 Mar 2021

Buck scientists develop a predictive model to help identify people at risk for severe COVID-19

Researchers at the Buck Institute analyzed data from the COVID-19 Symptom Tracker app used by 3 million people in the United Kingdom, adding the use of immunosuppressant medication, use of a mobility aid, shortness of breath, fever, and fatigue to the list of symptoms and comorbidities that increase the risk for severe COVID-19.

9 Mar 2021

SARS-CoV-2's amyloid-driving nucleoprotein could inform future therapeutic research

New research led by researchers at the University of California Los Angeles and the University of Texas Southwestern Medical Center in the US suggests that functional amyloid fibrils could play an integral role in developing COVID-19 treatments.

9 Mar 2021

Inhibition of complement disrupts neurodegeneration, improves cognitive function in TBI patients

Traumatic brain injury (TBI) is a major cause of disability and a risk factor for early-onset dementia. The injury is characterized by a physical insult followed acutely by complement driven neuroinflammation.

9 Mar 2021

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

A new study of the U.K. and South Africa variants of SARS-CoV-2 predicts that current vaccines and certain monoclonal antibodies may be less effective at neutralizing these variants and that the new variants raise the specter that reinfections could be more likely.

8 Mar 2021

Weedy grass may be effective against several human diseases

Native to the southeastern United States, a weedy grass has spread northward to Canada and also made its way to Australia and Japan. Andropogon virginicus grows densely packed and up to seven feet tall, disrupting growth patterns of other plants and competing for resources.

8 Mar 2021

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.

8 Mar 2021

Study shows how mutant huntingtin protein triggers brain cell death

In 1993, scientists discovered that a single mutated gene, HTT, caused Huntington's disease, raising high hopes for a quick cure. Yet today, there's still no approved treatment.

7 Mar 2021

Artificial intelligence can predict risk of new-onset atrial fibrillation and AF-related stroke

A team of scientists from Geisinger and Tempus have found that artificial intelligence can predict risk of new atrial fibrillation (AF) and AF-related stroke.

5 Mar 2021

Combined liver-cytokine humanization enhances human red blood cell production and survival

In a new study by the Yale Department of Immunobiology and Yale Cancer Center, researchers report combined liver and growth factor humanization enhances human red blood cell production and survival in circulation the immunodeficient murine host.

5 Mar 2021

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198.

5 Mar 2021

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. Image credit: Shutterstock.com/Billion Photos

From Aptamer Group 5 Mar 2021

Therapeutics News and Research

Mosquito protein study could lead to therapeutics against deadly viruses

NTU scientists design new compound that could help reduce overactive immune response

Tiny antibodies naturally generated by llamas can be effective against COVID-19

New compound can reduce overactivation without impairing the body's immunity response

Both ventral and dorsal surgeries improve outcomes in patients with cervical spondylotic myelopathy

New analysis shows SARS-CoV-2 mutations rarely persist in subsequent transmissions

Project Helios launched to unlock new approaches in small molecule drug discovery

Five herbal medicines show potent activity against Babesia duncani in the lab

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

Buck scientists develop a predictive model to help identify people at risk for severe COVID-19

SARS-CoV-2's amyloid-driving nucleoprotein could inform future therapeutic research

Inhibition of complement disrupts neurodegeneration, improves cognitive function in TBI patients

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

Weedy grass may be effective against several human diseases

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Study shows how mutant huntingtin protein triggers brain cell death

Artificial intelligence can predict risk of new-onset atrial fibrillation and AF-related stroke

Combined liver-cytokine humanization enhances human red blood cell production and survival

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News